Collegium Historical Income Statement

COLL Stock

USD 30.50 0.21 0.68%

Historical analysis of Collegium Pharmaceutical income statement accounts such as Interest Expense of 87.5 M, Selling General Administrative of 97.6 M or Other Operating Expenses of 222.1 M can show how well Collegium Pharmaceutical performed in making a profits. Evaluating Collegium Pharmaceutical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Collegium Pharmaceutical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Collegium Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Collegium Pharmaceutical is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.

About Collegium Income Statement Analysis

Collegium Pharmaceutical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Collegium Pharmaceutical shareholders. The income statement also shows Collegium investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Collegium Pharmaceutical Income Statement Chart

At this time, Collegium Pharmaceutical's Income Before Tax is quite stable compared to the past year. Net Income is expected to rise to about 50.6 M this year, although the value of Other Operating Expenses will most likely fall to about 222.1 M.

Selling General Administrative Other Operating Expenses Total Operating Expenses Selling And Marketing Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Collegium Pharmaceutical. It is also known as Collegium Pharmaceutical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Collegium Pharmaceutical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Collegium Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.At this time, Collegium Pharmaceutical's Income Before Tax is quite stable compared to the past year. Net Income is expected to rise to about 50.6 M this year, although the value of Other Operating Expenses will most likely fall to about 222.1 M.

	2021	2022	2023	2024 (projected)
Interest Expense	21.0M	63.2M	83.3M	87.5M
Depreciation And Amortization	68.9M	134.4M	149.3M	156.7M

Interest Expense Depreciation And Amortization

Collegium Pharmaceutical income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Net Income From Continuing Ops	Cost Of Revenue	Non Operating Income Net Other	Net Interest Income	Interest Income	Selling And Marketing Expenses	Reconciled Depreciation	Tax Provision	Non Recurring
Depreciation And Amortization		0.94	0.76	0.82	0.56	0.63	-0.87	0.87	0.77	0.64	-0.94	0.54	-0.08	0.94	0.56	0.83	0.61	-0.95	0.73	-0.63	0.96	0.19	-0.67
Interest Expense	0.94		0.66	0.71	0.68	0.82	-0.9	0.96	0.66	0.74	-1.0	0.58	0.24	0.96	0.6	0.73	0.46	-0.99	0.85	-0.75	0.86	0.33	-0.79
Selling General Administrative	0.76	0.66		0.95	0.13	0.27	-0.72	0.54	1.0	0.21	-0.65	0.25	-0.24	0.76	0.24	0.88	0.81	-0.7	0.41	-0.43	0.82	-0.04	-0.28
Other Operating Expenses	0.82	0.71	0.95		0.22	0.38	-0.73	0.63	0.95	0.36	-0.7	0.39	-0.22	0.81	0.37	0.98	0.84	-0.76	0.45	-0.46	0.88	0.0	-0.29
Operating Income	0.56	0.68	0.13	0.22		0.79	-0.61	0.76	0.12	0.89	-0.69	0.65	0.37	0.68	0.65	0.29	0.2	-0.58	0.91	-0.4	0.4	0.52	-0.88
Ebit	0.63	0.82	0.27	0.38	0.79		-0.69	0.93	0.28	0.92	-0.83	0.78	0.55	0.79	0.79	0.44	0.08	-0.79	0.79	-0.83	0.52	0.29	-0.78
Research Development	-0.87	-0.9	-0.72	-0.73	-0.61	-0.69		-0.85	-0.7	-0.63	0.9	-0.49	-0.16	-0.9	-0.5	-0.72	-0.59	0.89	-0.8	0.59	-0.8	-0.3	0.73
Ebitda	0.87	0.96	0.54	0.63	0.76	0.93	-0.85		0.54	0.88	-0.97	0.75	0.31	0.94	0.76	0.67	0.34	-0.95	0.85	-0.82	0.78	0.27	-0.8
Total Operating Expenses	0.77	0.66	1.0	0.95	0.12	0.28	-0.7	0.54		0.21	-0.65	0.25	-0.24	0.76	0.25	0.89	0.8	-0.7	0.4	-0.45	0.82	-0.05	-0.27
Income Before Tax	0.64	0.74	0.21	0.36	0.89	0.92	-0.63	0.88	0.21		-0.75	0.87	0.33	0.76	0.88	0.45	0.16	-0.7	0.78	-0.66	0.52	0.29	-0.75
Total Other Income Expense Net	-0.94	-1.0	-0.65	-0.7	-0.69	-0.83	0.9	-0.97	-0.65	-0.75		-0.58	-0.26	-0.95	-0.6	-0.72	-0.45	0.99	-0.86	0.75	-0.86	-0.34	0.79
Net Income	0.54	0.58	0.25	0.39	0.65	0.78	-0.49	0.75	0.25	0.87	-0.58		0.03	0.67	1.0	0.46	0.1	-0.56	0.53	-0.7	0.48	-0.2	-0.51
Income Tax Expense	-0.08	0.24	-0.24	-0.22	0.37	0.55	-0.16	0.31	-0.24	0.33	-0.26	0.03		0.11	0.03	-0.19	-0.29	-0.19	0.38	-0.3	-0.19	0.61	-0.41
Gross Profit	0.94	0.96	0.76	0.81	0.68	0.79	-0.9	0.94	0.76	0.76	-0.95	0.67	0.11		0.68	0.82	0.59	-0.94	0.82	-0.73	0.86	0.22	-0.76
Net Income From Continuing Ops	0.56	0.6	0.24	0.37	0.65	0.79	-0.5	0.76	0.25	0.88	-0.6	1.0	0.03	0.68		0.45	0.06	-0.58	0.53	-0.74	0.49	-0.2	-0.52
Cost Of Revenue	0.83	0.73	0.88	0.98	0.29	0.44	-0.72	0.67	0.89	0.45	-0.72	0.46	-0.19	0.82	0.45		0.82	-0.77	0.48	-0.45	0.89	0.04	-0.31
Non Operating Income Net Other	0.61	0.46	0.81	0.84	0.2	0.08	-0.59	0.34	0.8	0.16	-0.45	0.1	-0.29	0.59	0.06	0.82		-0.46	0.4	0.04	0.64	0.22	-0.25
Net Interest Income	-0.95	-0.99	-0.7	-0.76	-0.58	-0.79	0.89	-0.95	-0.7	-0.7	0.99	-0.56	-0.19	-0.94	-0.58	-0.77	-0.46		-0.77	0.77	-0.9	-0.26	0.7
Interest Income	0.73	0.85	0.41	0.45	0.91	0.79	-0.8	0.85	0.4	0.78	-0.86	0.53	0.38	0.82	0.53	0.48	0.4	-0.77		-0.48	0.58	0.54	-0.94
Selling And Marketing Expenses	-0.63	-0.75	-0.43	-0.46	-0.4	-0.83	0.59	-0.82	-0.45	-0.66	0.75	-0.7	-0.3	-0.73	-0.74	-0.45	0.04	0.77	-0.48		-0.59	0.12	0.49
Reconciled Depreciation	0.96	0.86	0.82	0.88	0.4	0.52	-0.8	0.78	0.82	0.52	-0.86	0.48	-0.19	0.86	0.49	0.89	0.64	-0.9	0.58	-0.59		0.09	-0.44
Tax Provision	0.19	0.33	-0.04	0.0	0.52	0.29	-0.3	0.27	-0.05	0.29	-0.34	-0.2	0.61	0.22	-0.2	0.04	0.22	-0.26	0.54	0.12	0.09		-0.49
Non Recurring	-0.67	-0.79	-0.28	-0.29	-0.88	-0.78	0.73	-0.8	-0.27	-0.75	0.79	-0.51	-0.41	-0.76	-0.52	-0.31	-0.25	0.7	-0.94	0.49	-0.44	-0.49

Click cells to compare fundamentals

Collegium Pharmaceutical Account Relationship Matchups

Collegium Pharmaceutical income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	15.8M	61.6M	68.9M	134.4M	149.3M	156.7M
Interest Expense	909K	28.9M	21.0M	63.2M	83.3M	87.5M
Selling General Administrative	116.4M	108.5M	114.8M	160.4M	151.8M	97.6M
Other Operating Expenses	320.4M	253.8M	254.7M	430.6M	399.8M	222.1M
Operating Income	(23.7M)	(5.1M)	(46.7M)	(104.6M)	167.0M	175.3M
Ebit	(37.6M)	56.5M	17.6M	34.4M	159.1M	167.0M
Research Development	8.7M	10.3M	9.8M	9.5M	4.0M	0.0
Ebitda	(21.8M)	118.1M	86.6M	168.8M	308.3M	323.7M
Total Operating Expenses	126.8M	123.6M	128.4M	176.2M	159.2M	110.7M
Income Before Tax	(22.7M)	27.6M	(3.4M)	(28.8M)	75.7M	79.5M
Total Other Income Expense Net	1.0M	(28.7M)	(21.0M)	(62.2M)	(91.2M)	(86.7M)
Net Income	(8.1M)	26.8M	71.5M	(25.0M)	48.2M	50.6M
Income Tax Expense	(14.6M)	830K	(74.9M)	(3.8M)	27.6M	29.0M
Total Revenue	296.7M	310.0M	276.9M	463.9M	566.8M	595.1M
Gross Profit	103.0M	179.8M	150.6M	209.5M	326.2M	342.5M
Net Income From Continuing Ops	(22.7M)	26.8M	71.5M	(25.0M)	48.2M	50.6M
Cost Of Revenue	193.7M	130.2M	126.3M	254.4M	240.6M	122.5M
Net Income Applicable To Common Shares	(22.7M)	26.8M	71.5M	(25.0M)	(28.8M)	(30.2M)
Non Operating Income Net Other	1.9M	232K	12K	1.0M	1.2M	694.8K
Net Interest Income	1.0M	(28.7M)	(21.0M)	(62.2M)	(67.7M)	(64.3M)
Interest Income	1.9M	232K	12K	1.0M	15.6M	16.4M
Selling And Marketing Expenses	116.4M	5.4M	4.2M	11.7M	7.4M	7.0M
Reconciled Depreciation	15.5M	61.6M	68.9M	138.9M	149.3M	85.7M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Collegium Pharmaceutical is a strong investment it is important to analyze Collegium Pharmaceutical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Collegium Pharmaceutical's future performance. For an informed investment choice regarding Collegium Stock, refer to the following important reports:

How To Invest In Collegium

Details

Is Collegium Stock a good investment?

Details

What is Collegium Pharmaceutical's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.

You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.49)

Earnings Share

2.34

Revenue Per Share

18.538

Quarterly Revenue Growth

0.165

Return On Assets

0.0968

The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Collegium Historical Income Statement

About Collegium Income Statement Analysis

Collegium Pharmaceutical Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Collegium Pharmaceutical income statement Correlations

Collegium Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Collegium Pharmaceutical income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Selling General Administrative
Net Income From Continuing Ops	+ 1.0	Net Income
Net Interest Income	+ 0.99	Total Other Income Expense Net
Cost Of Revenue	+ 0.98	Other Operating Expenses
Reconciled Depreciation	+ 0.96	Depreciation And Amortization
Ebitda	+ 0.96	Interest Expense

Total Other Income Expense Net	- 1.0	Interest Expense
Net Interest Income	- 0.99	Interest Expense
Total Other Income Expense Net	- 0.97	Ebitda
Gross Profit	- 0.95	Total Other Income Expense Net
Net Interest Income	- 0.95	Ebitda
Net Interest Income	- 0.95	Depreciation And Amortization